TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma
文献类型：期刊论文
| 作者 | Tao, Yi3; Yang, Guang3; Yang, Hongxing1,2; Song, Dongliang3; Hu, Liangning3; Xie, Bingqian3; Wang, Houcai3; Gao, Lu3; Gao, Minjie3; Xu, Hongwei5 |
| 刊名 | ONCOTARGET
 |
| 出版日期 | 2017-04-18 |
| 卷号 | 8期号:16页码:26718-26731 |
| 关键词 | TRIP13 multiple myeloma prognosis drug resistance MAD2 |
| ISSN号 | 1949-2553 |
| DOI | 10.18632/oncotarget.14957 |
| 文献子类 | Article |
| 英文摘要 | AAA-ATPase TRIP13 is one of the chromosome instability gene recently established in multiple myeloma (MM), the second most common and incurable hematological malignancy. However, the specific function of TRIP13 in MM is largely unknown. Using sequential gene expression profiling, we demonstrated that high TRIP13 expression levels were positively correlated with progression, disease relapse, and poor prognosis in MM patients. Overexpressing human TRIP13 in myeloma cells prompted cell growth and drug resistance, and overexpressing murine TRIP13, which shares 93% sequence identity with human TRIP13, led to colony formation of NIH/3T3 fibroblasts in vitro and tumor formation in vivo. Meanwhile, the knockdown of TRIP13 inhibited myeloma cell growth, induced cell apoptosis, and reduced tumor burden in xenograft MM mice. Mechanistically, we observed that the overexpression of TRIP13 abrogated the spindle checkpoint and induced proteasome-mediated degradation of MAD2 primarily through the Akt pathway. Thus, our results demonstrate that TRIP13 may serve as a biomarker for MM disease development and prognosis, making it a potential target for future therapies. |
| WOS关键词 | GENE-EXPRESSION ; AAA-ATPASE ; CHROMATIN CONDENSATION ; OVARIAN-CANCER ; PROTEIN ; INSTABILITY ; PROGRESSION ; ACTIVATION ; AKT ; CHEMORESISTANCE |
| 资助项目 | National Natural Science Foundation of China[81372391] ; National Natural Science Foundation of China[81300443] ; National Natural Science Foundation of China[81570190] ; National Natural Science Foundation of China[81529001] ; Natural Science Foundation of Shanghai[13ZR1432400] ; Natural Science Foundation of Shanghai[14DZ2260400] |
| WOS研究方向 | Oncology ; Cell Biology |
| 语种 | 英语 |
| WOS记录号 | WOS:000399819700076 |
| 出版者 | IMPACT JOURNALS LLC |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/272697]  |
| 专题 | 药物发现与设计中心 |
| 通讯作者 | Zhan, Fenghuang; Shi, Jumei |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Chenshan Plant Sci Res Ctr, Shanghai 201602, Peoples R China; 2.Shanghai Chenshan Bot Garden, Shanghai Key Lab Plant Funct Genom & Resources, Shanghai 201602, Peoples R China; 3.Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Hematol, Shanghai 200072, Peoples R China; 4.Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, Drug Discovery & Design Ctr, Shanghai 201203, Peoples R China 5.Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; |
| 推荐引用方式 GB/T 7714 | Tao, Yi,Yang, Guang,Yang, Hongxing,et al. TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma[J]. ONCOTARGET,2017,8(16):26718-26731. |
| APA | Tao, Yi.,Yang, Guang.,Yang, Hongxing.,Song, Dongliang.,Hu, Liangning.,...&Shi, Jumei.(2017).TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma.ONCOTARGET,8(16),26718-26731. |
| MLA | Tao, Yi,et al."TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma".ONCOTARGET 8.16(2017):26718-26731. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。